Antiviral Drugs Advisory Commitee Meeting Announcement
Agenda
The committee will discuss new drug
application (NDA) 204671, sofosbuvir (an NS5B polymerase inhibitor), manufactured by Gilead Sciences, Inc., with a proposed indication for the treatment of chronic hepatitis C infection, in combination with other agents in adult patients with genotypes 1 to 6 and/or adult patients awaiting liver transplantation.
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm368560.